Abivax SA

Developing an oral miR-124 pathway modulator for ulcerative colitis and other inflammatory diseases.

Back to company catalog

Immunology / IBD · Oral small molecule / miR-124 modulation · Phase 3 complete / NDA planned Q4 2026

Compare report options